Shuttle Pharmaceuticals Provides Q2 2023 Corporate Update; At June 30, 2023, Shuttle Pharma’s Cash Balance Was $8.4M
Recent Highlights
On track to commence Phase II clinical study in the fourth quarter of 2023 for Ropidoxuridine, Shuttle Pharma's lead clinical sensitizer drug candidate.
Successfully completed the